Free Submission Public Relations &
Deutsch English


INC Research Strengthens Leadership for Strategic Advisory Services Unit

Print article Print article
Copyright © Thomson Reuters 2012. All rights reserved.
2012-12-06 17:59:24 -

Robert Ryan, PhD, appointed Vice President, Regulatory Strategy, Consulting and

Raleigh, N.C., Dec. 6, 2012 - INC Research, LLC, a therapeutically focused
clinical research organization (CRO) with a Trusted Process(®) for delivering
reliable results, today announced the appointment of Robert Ryan, PhD, as Vice
President, Regulatory Strategy, Consulting and Submissions. Dr. Ryan will
provide global leadership to position INC Strategic Advisory Services as a
market leader in regulatory consulting and submissions offerings. In this role
he will continue to build on the Company's strong reputation in helping
biopharmaceutical customers worldwide navigate through the complexities 
of the regulatory environment to accelerate their time to market. "Robert brings a unique blend of strategic leadership skills and international regulatory expertise that speaks to biopharmaceutical companies looking for guidance along the entire continuum of the drug development lifecycle," said Tim Dietlin, Senior Vice President, Global Consulting and Strategic Alliances. "Our Regulatory Consulting and Submissions team has a long history of exceptional work, and we look forward to continuing this track record under Robert's leadership." Dr. Ryan is an experienced senior regulatory affairs executive with more than two decades of experience in the biopharmaceutical industry. He brings a unique blend of scientific and business acumen to the position, having held regulatory and executive leadership positions in both the CRO and biopharmaceutical industries with companies such as Quintiles, PPD, Celtic Therapeutics and Schwarz Pharma. Most recently, he was Chairman of the Board for Levare, LLC, a CNS/pain pharmaceutical development company. Dr. Ryan has been directly involved in the approval of more than 20 drugs throughout his career. He holds a doctorate in toxicology from the University of North Carolina at Chapel Hill, master's degrees in pharmacokinetics and genetics. Dr. Ryan is a diplomate of the American Board of Toxicology. With a network of global locations and on-the-ground expertise in all key markets, INC Research is committed to delivering superior quality regulatory services to help customers design the most efficient product development programs. The Company supports customer needs across the entire product lifecycle, from early regulatory development strategy consultations to clinical trial and marketing authorization submissions and post-licensing support. INC Research's service portfolio ranges from new chemical entities (NCEs) to biologics, biosimilars, well-established substances 505(b)(2) pathway, generic drugs, devices and in vitro diagnostics. With in-house expertise in drug-device combination products and medical devices, the Company also is able to offer a range of strategic and operational services, including clinical investigation submissions and CE-marking (Conformité Européenne) expertise. For more information on INC Research's Regulatory Consulting and Submissions services, please visit the online Resource Library. About INC Research INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in all therapeutic areas and innovative pediatric and women's health trials. The company's Trusted Process(®) methodology and therapeutic foresight lead customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information, please visit or follow us at @inc_research. Contact: Lori Dorer, Media +1 (513) 345-1685 This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: INC RESEARCH, LLC via Thomson Reuters ONE [HUG#1663198]

Press Information:

Contact Person:

Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact | BidVertiser